Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine: Lucas Dennis, Michael Kling, Annie Murphy, Jennifer Romans, Troy Schurr

Foundation Medicine this week announced several changes to its executive leadership team:

  • Lucas Dennis has been appointed senior VP, head of R&D, overseeing the company's cancer diagnostic portfolio. Dennis joined Foundation Medicine in 2018 to lead product development form the company's liquid biopsy diagnostic portfolio.
  • Michael Kling has been named chief technology officer. He joined the company in 2019 and most recently served as senior VP, engineering. He has over 20 years of technology leadership experience in the healthcare and biotech spaces, and joined Foundation Medicine from UnitedHealth Group.
  • Annie Murphy is the new chief commercial officer, overseeing the development and execution of the company's global clinical commercial strategy. Murphy joined the company in 2015 and has held various commercial, global product strategy, and medical roles.
  • Jennifer Romans has been appointed senior VP, corporate affairs. She joined the company in 2020 to build a strong governmental affairs and public policy function. Prior to Foundation Medicine, Romans was the principal government affairs liaison for Lilly Oncology within Eli Lilly.
  • Troy Schurr has been named chief biopharma business officer, and will lead the company's collaborations with biotech and pharmaceutical partners. He joined Foundation Medicine in 2022 as VP, biopharma marketing and solutions. He has also previously held global marketing, product development, and sales leadership roles at several companies including Johnson & Johnson and Astellas Oncology.
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.